miRNAs作为子宫内膜异位症无创诊断标志物的更新:为何尚未达成共识
本叙述性综述检索PubMed 2016年1月1日至2026年9月1日文献,关键词为子宫内膜异位症、miRNA和生物标志物,共检索到238篇,经筛选后29篇纳入进一步评估。综述更新了该时段报道的miRNA,并讨论为何尚未就具有合适灵敏度和特异度的诊断miRNA达成共识,指出血清/血浆分离、RNA提取、扩增与数据归一化及溶血评估等方法学差异影响miRNA谱,亟需标准化流程。
要点
- 多种miRNA为候选生物标志物,但子宫内膜异位症与非患者间差异表达miRNA变异性大。
- 血样分离、RNA提取、扩增与归一化及溶血评估方法差异影响miRNA谱。
- 若要识别可用于无创诊断的miRNA,需建立血液miRNA检测标准化方案。
核心结论
- 子宫内膜异位症无创miRNA标志物研究仍在进行,尚未就具有合适灵敏度和特异度的诊断miRNA达成共识。
研究设计与样本
- 叙述性综述,检索PubMed 2016年1月1日至2026年9月1日,关键词为endometriosis、miRNA和biomarker,共检索238篇,29篇纳入进一步评估。
主要发现
- 238篇中101篇为综述、meta分析或数据库检索,46篇聚焦组织或细胞miRNA表达,24篇聚焦共病疾病,17篇聚焦外泌体,15篇聚焦其他体液,4篇聚焦AI/机器学习,2篇聚焦动物模型。
- 多种miRNA为候选生物标志物,但子宫内膜异位症与非患者间差异表达miRNA存在相当大变异。
关键数值与推荐
- 血清/血浆分离、RNA/miRNA提取、扩增与数据归一化及溶血评估的方法学差异影响miRNA谱。
- 需制定血液miRNA评估的标准化方案以识别可用于无创诊断的miRNA。
临床怎么用
- 临床解读miRNA诊断研究时需关注血样处理、RNA提取、扩增归一化及溶血评估等前分析变量。
- 在标准化方案建立前,不宜将单一miRNA作为子宫内膜异位症无创诊断依据。
局限性
- 本文为叙述性综述,未提供原始研究数据或定量合并分析。
- 纳入研究间方法学异质性大,影响miRNA标志物结论的一致性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objective of this narrative review is to provide an update on microRNAs (miRNAs) as non-invasive biomarkers for endometriosis diagnosis focusing on publications from 2016 to 2026. In addition to updating miRNAs reported during this time frame, we also discuss why consensus has not been reached on identification of miRNAs with suitable sensitivity and specificity as diagnostic markers. A literature search was performed on PubMed from January 1, 2016 to September 1, 2026 using the keywords endometriosis, miRNA, and biomarker. A total of 238 articles were retrieved of which 101 were reviews, meta-analysis, or database searches, 46 articles focused on tissue or cell assessment of miRNA expression limiting the non-invasive approach, 24 were not focused on endometriosis but diseases comorbid with endometriosis, 17 focused on exosomes, 15 focused on other body fluid assessment of miRNAs, 4 focused on AI/machine learning, and 2 focused on animal model assessment of miRNA expression leaving 29 publications for further evaluation. The search for non-invasive biomarkers for endometriosis remains ongoing. From the studies presented in this review, while several miRNAs have emerged as candidate biomarkers, there is still considerable variability with respect to differentially expressed miRNAs between women with and without endometriosis. Focused assessment on methodologies employed for isolating serum/plasma, extraction of RNA/miRNAs, amplification and data normalization from these samples and if and how sample hemolysis was assessed and revealed differences among the studies all which impact miRNA profiles. As such, it is imperative to develop a standardized protocol when assessing miRNAs from blood if we hope to identify miRNAs which may prove useful in non-invasive diagnosis of endometriosis.
引用
- Nothnick WB, Olig E, Findley A, et al. An update on miRNAs as non-invasive diagnostic markers for endometriosis: Why have we not reached consensus? J Minim Invasive Gynecol. 2026. PMID: 42854833. doi:10.1016/j.jmig.2026.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。